TSXV:BTI.H - Post by User
Post by
prophetoffactzon Dec 19, 2022 10:29am
188 Views
Post# 35179490
MTX110
MTX110 BTI's bold move places an important bet on Midatech's lead clinical asset MTX110. If this drug works Biodexa becomes a much stronger company, potentially. The lead trial with MTX110 is for an ultra-rare pediatric cancer.
Looks like some clinical data within about one month: "In addition, the company expects to report data in the next couple of months from the second Phase I study assessing MTX110 in DIPG, conducted by Columbia University." Edison Group November 15 Midatech Pharma - Patient recruitment begins in rGBM study | Edison (edisongroup.com) ------
"As a reminder, Midatech had earlier (in October 2020) presented interim data from its other UCSF conducted Phase I study, which not only met its primary endpoint in terms of safety but also demonstrated exceptionally positive early efficacy signals, including median overall survival of 26.06 months (CI 11.3–26.06 months) versus 10 months following standard of care radiation therapy." Midatech Pharma - Interim DIPG data to be presented at ISPNO | Edison (edisongroup.com)
Another clinical trial using MTX110 just enrolled its first patient recently and targets glioblastoma which is a $5 billion market. The trial for the ultra-rare pediatric cancer using the same drug and delivery technology would appear to support the glioblastoma trial.